<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03412305</url>
  </required_header>
  <id_info>
    <org_study_id>AB-IMP</org_study_id>
    <nct_id>NCT03412305</nct_id>
  </id_info>
  <brief_title>The Effect of Antibiotic Prophylaxis Associated With Dental Implant Surgery</brief_title>
  <official_title>Effect of Antibiotic Prophylaxis in Dental Implant Surgery - a Multicenter Placebo-controlled Double-blinded Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Malmö University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Malmö University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of the study is to investigate whether routine administration of antibiotic&#xD;
      prophylaxis 1 hour prior to implant surgery may prevent postoperative infection and implant&#xD;
      loss in healthy or substantially healthy patients (ASA Class 1 and Class 2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of bacteria resistant to antibiotics is increasing and there is a correlation&#xD;
      between high consumption of antibiotics and high incidence of antibiotic resistance. It is&#xD;
      therefore important to reduce the prescription of antibiotics. Antibiotics in dental care are&#xD;
      used to treat oral infections as well as to prevent infections associated with surgical&#xD;
      procedures. An example of the latter is antibiotic prophylaxis associated with dental implant&#xD;
      surgery in order to reduce the risk of postoperative infection that can lead to loss of&#xD;
      implant.The study will be conducted as a multicenter placebo-controlled randomized clinical&#xD;
      trial. Eligible patients will be asked for participation and those who leave oral and written&#xD;
      information will be included in the study. Patients included will be allocated to either&#xD;
      active treatment (antibiotic prophylaxis) or placebo. Both clinicians and patients will be&#xD;
      blinded to group affiliation. A total of 10 clinicians in 8 centers in the south of Sweden&#xD;
      have agreed to participate and each clinicians will be allowed to use the implants and&#xD;
      routines that they usually work with.&#xD;
&#xD;
      Specific aims of the study are to test the following hypotheses:&#xD;
&#xD;
        1. There is no difference in proportion of patients with early implant losses in patients&#xD;
           receiving 2 g of amoxicillin preoperatively and patients receiving identical placebo&#xD;
           tablets.&#xD;
&#xD;
        2. There is no difference in proportion of patients with early infections between patients&#xD;
           receiving 2 g of amoxicillin preoperatively and patients receiving identical placebo&#xD;
           tablets.&#xD;
&#xD;
        3. There is no difference in infections (within 3-6 months postoperatively) between&#xD;
           patients receiving 2 g of amoxicillin preoperatively and patients receiving identical&#xD;
           placebo tablets.&#xD;
&#xD;
      If it appears that antibiotic prophylaxis does not lead to any risk reduction, this result&#xD;
      may provide a basis for guidelines rejecting antibiotic prophylaxis in dental implant&#xD;
      surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">August 10, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The tablets corresponding to each patient is packed in a container by the manufacturer of the trial drug. Each drug container is labeled by a code number (1-1000) and the contents of the containers are distributed according to a randomization list with block size 6. Randomization is thus carried out by the manufacturer, independent of investigator and participating clinicians.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Implant failure</measure>
    <time_frame>3-6 months after implant placement</time_frame>
    <description>Early implant mobility and/or infection, which requires the implant to be removed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative infection</measure>
    <time_frame>7-14 days after implant placement</time_frame>
    <description>Presence of swelling, redness, pus, pain and wound dehiscence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>3-6 months after implant placement</time_frame>
    <description>Presence of any type of infection such as abscess, fistula</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">474</enrollment>
  <condition>Infection Control</condition>
  <condition>Antibiotic Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Amoxicillin oral tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 g amoxicillin tablets orally 1 hour before implant placement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets orally 1 hour before implant placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Antibiotic prophylaxis consisting of 4 amoxicillin tablets, totally 2 g, orally 1 hour before implant placement</description>
    <arm_group_label>Amoxicillin oral tablets</arm_group_label>
    <other_name>Amoxicillin oral tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo consisting of 4 tablets, orally 1 hour before implant placement</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo oral tablets (for Amoxicillin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Requirement for dental implant placement&#xD;
&#xD;
          -  Over 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immunosuppressed or immunocompromised&#xD;
&#xD;
          -  Affected by not controlled diabetes&#xD;
&#xD;
          -  Serious or severe systemic disease (ASA classification &gt; 2)&#xD;
&#xD;
          -  Previous radiotherapy to the head or neck area&#xD;
&#xD;
          -  Ongoing acute or chronic infection in the oral cavity&#xD;
&#xD;
          -  Ongoing treatment with antibiotics&#xD;
&#xD;
          -  Hypersensitivity to penicillin&#xD;
&#xD;
          -  Previous or ongoing treatment with bisphosphonates&#xD;
&#xD;
          -  In need of major bone augmentation&#xD;
&#xD;
          -  Planned direct loading or early loading (within 2 weeks) of the implant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bengt Götrick</last_name>
    <role>Principal Investigator</role>
    <affiliation>Malmö University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Malmö university</name>
      <address>
        <city>Malmö</city>
        <zip>20506</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Malmö University</investigator_affiliation>
    <investigator_full_name>Bengt Götrick</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>Dental implants, antibiotic prophylaxis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

